This Article Abstract Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Sdringola, S. Articles by Gould, K. L. Search for Related Content PubMed PubMed Citation Articles by Sdringola, S. Articles by Gould, K. L.

Combined intense lifestyle and pharmacologic lipid treatment further reduce coronary events and myocardial perfusion abnormalities compared with usual-care cholesterol-lowering drugs in coronary artery disease

Stefano Sdringola, MD, FACC^*, Keiichi Nakagawa, MD, Yuko Nakagawa, MD, S. Wamique Yusuf, MBBS, MRCP, Fernando Boccalandro, MD, Nizar Mullani, BS^*, Mary Haynie, RN, MBA^*, Mary Jane Hess, RN^* and K. Lance Gould, MD, FACC^*,*

^* Weatherhead P.E.T. Center for Preventing and Reversing Atherosclerosis, Houston, Texas, USA
Department of Medicine, Division of Cardiology, University of Texas Medical School at Houston, Houston, Texas, USA
Third Department of Internal Medicine, Chiba University School of Medicine, Chiba, Japan

View larger version (72K): [in a new window]   Figure 1 Examples of dipyridamole positron emission tomography with improved perfusion indicating regression (A) and with worsening perfusion indicating progression of coronary artery disease (B). Three-dimensional topographic views from left to right are lateral (Lat), inferior (Inf), septal (Sep), and anterior (Ant) views. The upper row is after dipyridamole at baseline, and the lower row is after dipyridamole at follow-up. Resting perfusion images were normal (not shown). Red = the highest flow; yellow = intermediate; green and blue = progressively lower perfusion in continuous graded steps according to the color bar.

View larger version (18K): [in a new window]   Figure 2 Changes in the quantitative severity of myocardial perfusion abnormalities by dipyridamole positron emission tomography.

View larger version (18K): [in a new window]   Figure 3 Changes in the size of myocardial perfusion abnormalities.

View larger version (18K): [in a new window]   Figure 4 Changes in the combined size and severity of myocardial perfusion abnormalities.

View larger version (23K): [in a new window]   Figure 5 Cardiovascular events at the end of five-year follow-up. CABG = coronary artery bypass graft; MI = myocardial infarction; PTCA = percutaneous transluminal coronary angioplasty.

View larger version (23K): [in a new window]   Figure 6 Cumulative probability of cardiovascular events during five-year follow-up. See text for explanation of values of n and size of treatment (Rx) groups.